Cargando…

Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine

Aplidine, dehydrodidemnin B, is a marine depsipeptide isolated from the Mediterranean tunicate Aplidium albicans currently in phase II clinical trial. In human Molt-4 leukaemia cells Aplidine was found to be cytotoxic at nanomolar concentrations and to induce both a G(1) arrest and a G(2) blockade....

Descripción completa

Detalles Bibliográficos
Autores principales:	Erba, E, Bassano, L, Di Liberti, G, Muradore, I, Chiorino, G, Ubezio, P, Vignati, S, Codegoni, A, Desiderio, M A, Faircloth, G, Jimeno, J, D'Incalci, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375382/ https://www.ncbi.nlm.nih.gov/pubmed/11986788 http://dx.doi.org/10.1038/sj.bjc.6600265

Ejemplares similares

Effect of Aplidin in acute lymphoblastic leukaemia cells
por: Erba, E, et al.
Publicado: (2003)

Antiangiogenic activity of aplidine, a new agent of marine origin
por: Taraboletti, G, et al.
Publicado: (2004)

Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743)
por: Erba, E, et al.
Publicado: (2000)

Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound
por: Bergamaschi, D, et al.
Publicado: (1999)

Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin™
por: Losada, A, et al.
Publicado: (2004)

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells.
por: Depenbrock, H., et al.
Publicado: (1998)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Mode of action of thiocoraline, a natural marine compound with anti-tumour activity
por: Erba, E, et al.
Publicado: (1999)

Mitozolomide activity on human cancer cells in vitro.
por: Erba, E., et al.
Publicado: (1986)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

In vitro interaction between Ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects
por: Simoens, C, et al.
Publicado: (2003)

Flow cytometric analysis of DNA content in human ovarian cancers.
por: Erba, E., et al.
Publicado: (1989)

IDN 5390: an oral taxane candidate for protracted treatment schedules
por: Pratesi, G, et al.
Publicado: (2003)

Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors.
por: Desiderio, M. A., et al.
Publicado: (1997)

Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer
por: Barnes, N L P, et al.
Publicado: (2007)

Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
por: D'Incalci, M., et al.
Publicado: (1980)

Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
por: Laudonio, N., et al.
Publicado: (1990)

Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.
por: Sen, S., et al.
Publicado: (1996)

Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
por: Erba, E., et al.
Publicado: (1994)

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
por: D'Incalci, M, et al.
Publicado: (2014)

Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512).
por: Pratesi, G., et al.
Publicado: (1988)

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB
por: Camorani, Simona, et al.
Publicado: (2018)

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
por: Borjan, Bojana, et al.
Publicado: (2015)

The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
por: Duverger, V, et al.
Publicado: (2004)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Flavonoids uptake and their effect on cell cycle of human colon adenocarcinoma cells (Caco2)
por: Salucci, M, et al.
Publicado: (2002)

Tracking the cell cycle origins for escape from topotecan action by breast cancer cells
por: Feeney, G P, et al.
Publicado: (2003)

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
por: Santin, A D, et al.
Publicado: (2002)

Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008)

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012)

Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells
por: Scheffer, G L, et al.
Publicado: (2002)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
por: Stingl, L, et al.
Publicado: (2010)

Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment
por: Lee, W-N P, et al.
Publicado: (2004)

An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells
por: Heuser, C, et al.
Publicado: (2003)

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts
por: Delgado-Calle, Jesus, et al.
Publicado: (2019)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3igp62hs0dafs4pr3sn3bk5s9l